Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no add ...

Key Takeaways TMO faces margin pressure from weak macro trends, supply disruptions and rising operating expenses. Foreign exchange volatility and global expansion heighten risk to Thermo Fisher's international revenues. TMO's $4.1B Solventum deal aims to boost biologics growth and deliver $125M in synergy over five years.Thermo Fisher (TMO) suffers from macroeconomic issues. Also, competitive headwinds and currency fluctuations continue to dampen top-line growth. The stock carries a Zacks Rank #4 (Sell) c ...

I grant Thermo Fisher (NYSE: TMO ) (NEOE: TMO:CA ) a Buy rating. In my opinion, the company has been successful in investing significant financial resources to expand its operations. To grant context, TMO dedicated, on average, 16.51% of its revenues to capitalDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for ...

公司表现与市场反应 - Thermo Fisher Scientific在2025年初因令人失望的业绩指引和地缘政治紧张局势加剧而受到关注 [1] - 新出台的美中关税预计将对公司造成成本压力 [1] 投资者偏好 - 投资者关注公司在收入、盈利和自由现金流方面的增长 [1] - 投资者偏好具有良好增长前景的公司 [1] - 投资者青睐估值有利的股票 [1] - 投资者偏好自由现金流利润率高的稳定增长公司、派息股票以及有慷慨股票回购计划的公司 [1]

Thermo Fisher Scientific (TMO) has unveiled its latest innovation, the spectral-enabled Invitrogen Attune Xenith Flow Cytometer. The solution allows immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples.The Attune Xenith Flow Cytometer is the latest advancement in the company’s extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments.Likely Trend of TMO Stock Followi ...

Thermo Fisher Scientific Inc. TMO is currently navigating a rare and telling phase in its journey through the Adhishthana Cycle. The stock is in its 18th Phase, simultaneously on both the weekly and monthly charts, a unique alignment that brings a powerful cyclical signal. Yet, while this convergence might appear synchronistic, the behavior across these timeframes paints two vastly different narratives.Where Are We in the Cycle?Fig.1 TMO Adhishthana Phases (Source: Adhishthana.com)TMO is now in the 18th and ...

公司新产品发布 - 公司推出新一代TruNarc Delta和Tau手持式毒品分析仪，采用非接触技术并扩展化学物质库，可现场快速检测超过1200种物质（包括兴奋剂、镇静剂、致幻剂和镇痛剂），即使低浓度或混合物也能识别 [1] - 新产品基于2012年推出的第一代TruNarc分析仪改进，该设备已被美国50个州和50多个国家的执法机构采用 [2] - 新型号采用更新工业设计，优化用户界面并提升性能，自动记录功能可生成完整扫描数据文档以加速法律程序，设备化学库会定期更新以应对新型毒品威胁 [6] 产品市场背景 - 美国每年因阿片类药物（如芬太尼）滥用导致超10万人死亡，执法人员面临误接触风险及现场识别毒品的挑战，新产品可帮助从安全距离检测截获物质以阻断跨境毒品流通 [5] - 2024年美国手持毒品分析仪市场规模达2.548亿美元，预计到2033年复合年增长率为3.8%，增长动力来自毒品滥用问题加剧、执法需求严格及海关/医疗领域检测技术快速普及 [7] 公司财务与股价表现 - 公司市值1486亿美元，2025年盈利预计增长2.1%，过去四个季度平均盈利超预期2.3% [4] - 新产品发布次日股价上涨0.6%至400.48美元，市场情绪预计将获提振 [3] - 过去六个月股价下跌24.5%，同期行业跌幅为13.4% [11] 其他业务进展 - 上月宣布采用增强平台技术和新型CHO K-1细胞系，可将新药研究申请时间从13个月缩短至9个月，该细胞系蛋白表达量达8g/L，显著提升生产稳定性与效率 [10] 行业比较数据 - Phibro Animal Health(PAHC)过去一年股价上涨25.3%，2025年EPS预期上调3.6%至2.01美元，盈利收益率8.7%显著高于行业0.5%，过去四季平均盈利超预期30.6% [13] - Hims & Hers Health(HIMS)过去一年股价暴涨224.9%，2025年EPS预期上调12.5%至0.72美元，过去四季平均盈利超预期19.6% [14] - Prestige Consumer Healthcare(PBH)过去一年股价上涨34%，2026年EPS预期上调至4.77美元，过去四季平均盈利超预期2.8% [15]

A month has gone by since the last earnings report for Thermo Fisher Scientific (TMO) . Shares have lost about 6.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Thermo Fisher due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Th ...

Thermo Fisher Scientific (TMO) FY 2025 Annual General Meeting May 21, 2025 08:30 AM ET Speaker0 Welcome to the twenty twenty five Annual Meeting of Shareholders of Thermo Fisher Scientific. I would now like to introduce the first presenter, Mr. Mark Casper, Chairman, President, and Chief Executive Officer of Thermo Fisher Scientific Inc. Thank you, and good morning to all attending Thermo Fisher's twenty twenty five Annual Meeting. I'm Mark Casper, Chairman, President and Chief Executive Officer of Thermo F ...

Marc N. Casper Chairman, President and Chief Executive Officer Julia L. Chen Vice President and Corporate Secretary Annual Meeting of Shareholders 2025 The world leader in serving science Proprietary | May 21, 2025 Annual Meeting of Shareholders Meeting Agenda 2 Proprietary | May 21, 2025 • Call to Order and Instructions • Voting Matters • Questions and Answers on Voting Matters • Closing of Polls • Preliminary Voting Report • Management Presentation • Questions and Answers on General Matters • Adjournment ...